Laura Bucci, Sebastian Boeltz, Melanie Hagen, Carlo Tur, Danae-Mona Nöthling, Tobias Rothe, Andreas Wirsching, Janina Auth, Jochen Wacker, Markus Eckstein, Stefano Alivernini, Aline Bözec, Christina Bergmann, Maria Antonietta D’Agostino, Luis E. Muñoz, Jürgen Rech, Lars Kihm, Maria Gabriella Raimondo, Georg Schett, Ricardo Grieshaber‐Bouyer
Teclistamab, a T-cell engager targeting B-cell maturation antigen, showed promise as a rescue therapy in 10 patients with refractory autoimmune diseases and led to clinical and serologic improvements in most patients.